• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD133和SOX2在晚期癌症中的预后价值

Prognostic Value of CD133 and SOX2 in Advanced Cancer.

作者信息

Han Susu, Huang Tao, Wu Xing, Wang Xiyu, Liu Shanshan, Yang Wei, Shi Qi, Li Hongjia, Hou Fenggang

机构信息

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 274 Zhijiang Road, Shanghai 200071, China.

The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315020, China.

出版信息

J Oncol. 2019 Jan 1;2019:3905817. doi: 10.1155/2019/3905817. eCollection 2019.

DOI:10.1155/2019/3905817
PMID:30693028
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6332999/
Abstract

BACKGROUND

The prognostic value of CD133 and SOX2 expression in advanced cancer remains unclear. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients.

METHODS

Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Trial sequential analysis (TSA) was also performed.

RESULTS

13 studies with 1358 cases (CD133) and five studies with 433 cases (SOX2) were identified. CD133 positivity was correlated with worse CSS and OS, but there was no correlation between CD133 positivity and DFS. SOX2 positivity was associated with poor DFS and RFS but was not linked to PFS. Stratified analysis by study source showed that only CD133 positivity can decrease OS for Chinese patients. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. TSA showed that additional studies were necessary.

CONCLUSIONS

CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed.

IMPACT

CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients.

摘要

背景

CD133和SOX2表达在晚期癌症中的预后价值仍不明确。本研究首次探讨CD133或SOX2阳性与晚期癌症患者临床结局之间的关联。

方法

计算95%置信区间（95%CI）的风险比（HR），以评估多变量分析中CD133或SOX2阳性与总生存期（OS）、无病生存期（DFS）、无进展生存期（PFS）、癌症特异性生存期（CSS）或无复发生存期（RFS）之间的相关性。还进行了试验序贯分析（TSA）。

结果

共纳入13项研究中的1358例患者（CD133）和5项研究中的433例患者（SOX2）。CD133阳性与较差的CSS和OS相关，但CD133阳性与DFS之间无相关性。SOX2阳性与较差的DFS和RFS相关，但与PFS无关。按研究来源进行分层分析显示，仅CD133阳性可降低中国患者的OS。按治疗方案进行分层分析表明，CD133阳性与接受辅助治疗患者较差的OS相关。TSA显示需要更多研究。

结论

CD133和SOX2可能与晚期癌症预后较差有关。强烈需要更多前瞻性研究。

影响

CD133和SOX2可能是晚期癌症患者有前景的靶向分子治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/8f0342708cea/JO2019-3905817.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/97f165869fb7/JO2019-3905817.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/e7788b7d2960/JO2019-3905817.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/40d3d489c3ba/JO2019-3905817.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/6aa66620b24f/JO2019-3905817.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/accf993abb4b/JO2019-3905817.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/f15a8baf049b/JO2019-3905817.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/8f0342708cea/JO2019-3905817.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/97f165869fb7/JO2019-3905817.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/e7788b7d2960/JO2019-3905817.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/40d3d489c3ba/JO2019-3905817.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/6aa66620b24f/JO2019-3905817.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/accf993abb4b/JO2019-3905817.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/f15a8baf049b/JO2019-3905817.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dab/6332999/8f0342708cea/JO2019-3905817.007.jpg

相似文献

1
Prognostic Value of CD133 and SOX2 in Advanced Cancer.CD133和SOX2在晚期癌症中的预后价值
J Oncol. 2019 Jan 1;2019:3905817. doi: 10.1155/2019/3905817. eCollection 2019.
2
Prognostic value of ALDH1 and Nestin in advanced cancer: a systematic meta-analysis with trial sequential analysis.ALDH1和巢蛋白在晚期癌症中的预后价值：一项采用试验序贯分析的系统Meta分析
Ther Adv Med Oncol. 2019 Feb 25;11:1758835919830831. doi: 10.1177/1758835919830831. eCollection 2019.
3
Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis.CD44及其异构体在晚期癌症中的预后价值：一项采用序贯试验分析的系统Meta分析
Front Oncol. 2019 Feb 6;9:39. doi: 10.3389/fonc.2019.00039. eCollection 2019.
4
The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis.缺氧诱导因子-1α在晚期癌症幸存者中的预后价值：一项采用试验序贯分析的荟萃分析
Ther Adv Med Oncol. 2019 Sep 24;11:1758835919875851. doi: 10.1177/1758835919875851. eCollection 2019.
5
Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.癌症干细胞相关标志物CD133和巢蛋白是否预示着胶质瘤患者的预后不良？一项系统评价和荟萃分析。
J Exp Clin Cancer Res. 2015 May 14;34(1):44. doi: 10.1186/s13046-015-0163-4.
6
The clinicopathological significance of CD133 and Sox2 in astrocytic glioma.CD133 和 Sox2 在星形细胞瘤中的临床病理意义。
Cancer Biomark. 2018;23(3):391-403. doi: 10.3233/CBM-181460.
7
Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis.胃癌患者中癌症干细胞标志物的临床及预后意义：一项系统评价与荟萃分析
Cancer Cell Int. 2021 Feb 27;21(1):139. doi: 10.1186/s12935-021-01840-z.
8
High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.高Ki-67免疫组化反应性与膀胱癌预后不良相关：一项纳入13053例患者的综合荟萃分析。
Medicine (Baltimore). 2016 Apr;95(15):e3337. doi: 10.1097/MD.0000000000003337.
9
Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis.性别决定区Y盒2在结直肠癌中的临床及生存影响：免疫组织化学研究与生物信息学分析的综合分析
J Oncol. 2020 Feb 13;2020:3761535. doi: 10.1155/2020/3761535. eCollection 2020.
10
Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis.八聚体结合转录因子4对实体瘤患者的预后价值：一项荟萃分析。
Medicine (Baltimore). 2020 Oct 16;99(42):e22804. doi: 10.1097/MD.0000000000022804.

引用本文的文献

1
Therapeutic and Prognostic Relevance of Cancer Stem Cell Populations in Endometrial Cancer: A Narrative Review.子宫内膜癌中癌症干细胞群的治疗及预后相关性：一项叙述性综述
Diagnostics (Basel). 2025 Jul 25;15(15):1872. doi: 10.3390/diagnostics15151872.
2
Effects of Ultra-Short Pulsed Electric Field Exposure on Glioblastoma Cells.超短脉冲电场暴露对神经胶质瘤细胞的影响。
Int J Mol Sci. 2022 Mar 10;23(6):3001. doi: 10.3390/ijms23063001.
3
Intrinsic and Extrinsic Factors Impacting Cancer Stemness and Tumor Progression.影响癌症干性和肿瘤进展的内在和外在因素

本文引用的文献

1
Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?社论：癌症化疗的不良反应：在提高耐受性和减少后遗症方面有什么新进展？
Front Pharmacol. 2018 Mar 22;9:245. doi: 10.3389/fphar.2018.00245. eCollection 2018.
2
Clinicopathological, prognostic and predictive value of CD166 expression in colorectal cancer: a meta-analysis.CD166表达在结直肠癌中的临床病理、预后及预测价值：一项荟萃分析
Oncotarget. 2017 Apr 26;8(38):64373-64384. doi: 10.18632/oncotarget.17442. eCollection 2017 Sep 8.
3
Is Ep-CAM Expression a Diagnostic and Prognostic Biomarker for Colorectal Cancer? A Systematic Meta-Analysis.
Cancers (Basel). 2022 Feb 15;14(4):970. doi: 10.3390/cancers14040970.
4
The clinical and prognostic impact of aldehyde dehydrogenase 1 in non-small cell lung cancer: a meta-analysis.醛脱氢酶1在非小细胞肺癌中的临床及预后影响：一项荟萃分析
Transl Cancer Res. 2020 Mar;9(3):1914-1925. doi: 10.21037/tcr.2020.02.09.
5
SOX2 and Bcl-2 as a Novel Prognostic Value in Hepatocellular Carcinoma Progression.SOX2 和 Bcl-2 作为肝细胞癌进展的新的预后价值。
Curr Oncol. 2021 Aug 9;28(4):3015-3029. doi: 10.3390/curroncol28040264.
6
The Clinical and Molecular Characteristics of Sex-Determining Region Y-Box 2 and its Prognostic Value in Breast Cancer: A Systematic Meta-Analysis.性别决定区Y盒2在乳腺癌中的临床和分子特征及其预后价值：一项系统的Meta分析
Breast Care (Basel). 2021 Feb;16(1):16-26. doi: 10.1159/000505806. Epub 2020 Mar 26.
7
Deregulation of extracellular matrix modeling with molecular prognostic markers revealed by transcriptome sequencing and validations in Oral Tongue squamous cell carcinoma.通过转录组测序和口腔舌鳞状细胞癌验证揭示的分子预后标志物对细胞外基质建模的调控失调。
Sci Rep. 2021 Jan 8;11(1):250. doi: 10.1038/s41598-020-78624-4.
8
Mitochondrial Stress-Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma.线粒体应激介导的口腔鳞状细胞癌中静止癌症干细胞的靶向作用
Cancer Manag Res. 2020 Jun 15;12:4519-4530. doi: 10.2147/CMAR.S252292. eCollection 2020.
9
Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis.性别决定区Y盒2在结直肠癌中的临床及生存影响：免疫组织化学研究与生物信息学分析的综合分析
J Oncol. 2020 Feb 13;2020:3761535. doi: 10.1155/2020/3761535. eCollection 2020.
10
A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression.基于上皮细胞黏附分子（EpCAM）表达的前列腺癌风险和预后的荟萃分析和癌症基因组图谱数据。
BMC Urol. 2019 Jul 19;19(1):67. doi: 10.1186/s12894-019-0499-8.
E-钙黏蛋白表达作为结直肠癌的诊断和预后生物标志物？系统荟萃分析。
EBioMedicine. 2017 Jun;20:61-69. doi: 10.1016/j.ebiom.2017.05.025. Epub 2017 May 24.
4
Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).癌症干细胞（CSC）抑制剂：近期专利综述（2012 - 2015年）
Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
5
Prognostic Value of Cancer Stem Cell Markers in Head and Neck Squamous Cell Carcinoma: a Meta-analysis.头颈部鳞状细胞癌中癌症干细胞标志物的预后价值：一项荟萃分析。
Sci Rep. 2017 Feb 21;7:43008. doi: 10.1038/srep43008.
6
Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.Sox2 依赖的 p21 抑制与子宫内膜癌的不良预后相关。
Cancer Sci. 2017 Apr;108(4):632-640. doi: 10.1111/cas.13196. Epub 2017 Apr 19.
7
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.同期立体定向放疗与靶向治疗或免疫治疗的毒性：系统评价。
Cancer Treat Rev. 2017 Feb;53:25-37. doi: 10.1016/j.ctrv.2016.11.013. Epub 2016 Dec 19.
8
Resistance to Cell Death and Its Modulation in Cancer Stem Cells.癌症干细胞中对细胞死亡的抗性及其调控
Crit Rev Oncog. 2016;21(3-4):203-219. doi: 10.1615/CritRevOncog.2016016976.
9
SOX2 Determines Lineage Restriction: Modeling Lung Squamous Cell Carcinoma in the Mouse.SOX2 决定谱系限制：在小鼠中建立肺鳞状细胞癌模型。
Cancer Cell. 2016 Oct 10;30(4):505-507. doi: 10.1016/j.ccell.2016.09.012.
10
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.PI3K和SOX2对头颈部鳞状细胞癌干细胞的调控
J Natl Cancer Inst. 2016 Sep 15;109(1). doi: 10.1093/jnci/djw189. Print 2017 Jan.